26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models. - Evidence Based Medicine on FHIR Implementation Guide v2.0.0-ballot

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Citation: 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.

Active as of 2024-12-19

Generated Narrative: Citation 267500

version: 2; Last updated: 2024-11-22 19:28:54+0000

Profile: JournalArticleCitation

url: Citation 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.

identifier: FEvIR Object Identifier/https://fevir.net/FOI/267500, https://pubmed.ncbi.nlm.nih.gov/26502880, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.1

version: 2.0.0-ballot

title: 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.

status: Active

date: 2024-12-19 14:29:51+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

UseContexts

Code

Value[x]

Citation Classification Type fevir-platform-use: FEvIR Platform Use

Medline Base

jurisdiction: World

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

approvalDate: 2016-07-11

lastReviewDate: 2024-03-24

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification
type: Citation Source
classifier: MEDLINE

classification
type: MEDLINE Citation Owner
classifier: National Library of Medicine, Index Section

currentState: Medline Citation Status of Medline, PubMed PublicationStatus of epublish

statusDate
activity: PubMed Pubstatus of Received
period: ?? --> 2015-05-09

statusDate
activity: PubMed Pubstatus of Accepted
period: ?? --> 2015-09-21

statusDate
activity: PubMed Pubstatus of Entrez
period: ?? --> 2015-10-28 06:00:00+0000

statusDate
activity: PubMed Pubstatus of Pubmed
period: ?? --> 2015-10-28 06:00:00+0000

statusDate
activity: PubMed Pubstatus of Medline
period: ?? --> 2016-07-12 06:00:00+0000

statusDate
activity: PubMed Pubstatus of PMC release
period: ?? --> 2015-10-26

citedArtifact
identifier: https://pubmed.ncbi.nlm.nih.gov/26502880, https://www.ncbi.nlm.nih.gov/pmc//PMC4621930, https://doi.org/10.1186/s40360-015-0026-9, pii/10.1186/s40360-015-0026-9
Titles
- Type Language Text
* Primary title English
A novel nasal powder formulation of glucagon: toxicology studies in animal models.

Abstracts
- Text
*
BACKGROUND: Glucagon nasal powder (GNP), a novel intranasal formulation of glucagon being developed to treat insulin-induced severe hypoglycemia, contains synthetic glucagon (10% w/w), beta-cyclodextrin, and dodecylphosphocholine. The safety of this formulation was evaluated in four studies in animal models. METHODS: The first study evaluated 28-day sub-chronic toxicology in rats treated intranasally with 1 and 2 mg of GNP/day (0.1 and 0.2 mg glucagon/rat/day). The second study evaluated 28-day sub-chronic toxicology in dogs administered 20 and 40 mg of formulation/dog/day (2 and 4 mg glucagon/dog/day) intranasally. A pulmonary insufflation study assessed acute toxicology following intra-tracheal administration of 0.5 mg of GNP (0.05 mg glucagon) to rats. Local tolerance to 30 mg of GNP (equivalent to 3 mg glucagon, the final dose for humans) was tested through direct administration into the eyes of rabbits. RESULTS: There were no test article-related adverse effects on body weight and/or food consumption, ophthalmology, electrocardiography, hematology, coagulation parameters, clinical chemistry, urinalysis, or organ weights, and no macroscopic findings at necropsy in any study. In rats, direct intra-tracheal insufflation at a dose of 0.5 mg of GNP/rat (0.05 mg glucagon/rat) did not result in adverse clinical, macroscopic, or microscopic effects. In dogs, the only adverse findings following sub-chronic use were transient (<30 s) salivation and sneezing immediately post-treatment and mild to moderate reversible histological changes to the nasal mucosa. Daily dosing over 28 days in rats resulted in mild to moderate, unilateral or bilateral erosion/ulceration of the olfactory epithelium, frequently with minimal to mild, acute to sub-acute inflammation of the lamina propria at the dorsal turbinates of the nasal cavity in 2/10 males and 3/10 females in the high-dose group (0.2 mg glucagon/day). These lesions resolved completely over 14 days. Histological examination of tissues from both sub-chronic studies in dogs and rats revealed no microscopic findings. In rabbits, clinical observations noted in the GNP-treated eye and/or surrounding areas included ≥1 of the following: clear discharge, red conjunctiva, partial closure, and swelling of the peri-orbital area, which correlated with erythema and edema noted during ocular observations and grading. <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The studies reported here revealed no safety concerns associated with GNP in animal models. Studies published earlier have highlighted the local safety profile of intranasally administered cyclodextrins (a component of GNP). The choline group, the phosphate group, and the saturated 12-carbon aliphatic chain that are present in the dodecylphosphocholine excipient used in GNP are all present in the phospholipids and lecithins seen ubiquitously in mammalian cell membranes and are unlikely to pose safety concerns; this notion is supported by several studies conducted by the authors that revealed no safety concerns. Taken together, these results suggest that intranasal delivery of GNP holds promise as a future rescue medication for use by caregivers to treat insulin-induced hypoglycemic episodes in patients with type 1 or type 2 diabetes. CONCLUSION: This novel drug product is well tolerated in animal models.

relatesTo
type: cites
classifier: Journal Article
citation:
Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II Diabetes. Diabetologia. 2002;45:937–48. doi: 10.1007/s00125-002-0822-9.

Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/12136392/
resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/12136392
relatesTo
type: cites
citation:
Deary IJ. Symptoms of hypoglycaemia and effects on mental performance and emotions. In: Frier BM, Fisher M, editors. Hypoglycaemia in clinical diabetes. 2. Chicester, West Sussex, England: John Wiley & Sons Limited; 2007. pp. 25–48.

relatesTo
type: cites
classifier: Journal Article
citation:
Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26:1902–12. doi: 10.2337/diacare.26.6.1902.

Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/12766131/
resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/12766131
relatesTo
type: cites
classifier: Journal Article
citation:
Leckie AM, Graham MK, Grant JB, Ritchie PJ, Frier BM. Frequency, severity, and morbidity of hypoglycemia occurring in the workplace in people with insulin-treated diabetes. Diabetes Care. 2005;28:1333–8. doi: 10.2337/diacare.28.6.1333.

Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/15920048/
resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/15920048
relatesTo
type: cites
classifier: Journal Article
citation:
Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care. 2005;28:2948–61. doi: 10.2337/diacare.28.12.2948.

Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/16306561/
resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/16306561
relatesTo
type: cites
classifier: Journal Article
citation:
UK Hypoglycemia Study Group Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140–7. doi: 10.1007/s00125-007-0599-y.

Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/17415551/
resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/17415551
relatesTo
type: cites
citation:
Cryer PE. Hypoglycemia in diabetes: pathophysiology, prevalence, and prevention. Alexandria, VA: American Diabetes Association; 2009. The clinical problem of hypoglycemia in diabetes; pp. 1–15.

relatesTo
type: cites
classifier: Journal Article
citation:
American Diabetes Association Standards of medical care in diabetes—2015. Diabetes Care. 2015;38(suppl 1):S1–94.

Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/15618112/
resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/15618112
relatesTo
type: cites
citation:
Jain MK. Introduction to biological membranes. New York: John Wiley & Sons; 1988. Components of biological membranes; pp. 10–50.

relatesTo
type: cites
citation:
GLUCACON (glucagon for injection, rDNA origin) Product Monograph. Toronto, Ontario: Eli Lilly Canada Inc.; 2012 http://www.lilly.ca/en/pdf/product-monograph/04_rglucagon-pm_9july2012.pdf. Accessed 26 September 2015.

relatesTo
type: cites
citation:
GLUCAGEN® and GLUCAGEN® Hypokit 1 mg (glucagon) Product Monograph. Mississauga, Ontario: Novo Nordisk Canada Inc.; 2014. http://www.paladin-labs.com/our_products/PM_GlucaGen_EN.pdf. Accessed 26 September 2015.

relatesTo
type: cites
classifier: Journal Article
citation:
Root MA, Ellis J, Staub A. Effect of glucagon on insulin hypoglycemia. Proc Soc Exp Biol Med. 1954;85:507–11. doi: 10.3181/00379727-85-20934.

Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/13167121/
resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/13167121
relatesTo
type: cites
classifier: Journal Article
citation:
Eistrup C, Hjortkjaer RK, Pickersgill N, Virgo DM, Woolley AP. Glucagon produced by recombinant DNA technology: repeated dose toxicity studies, intravenous administration to CD rats and beagle dogs for four weeks. Pharmacol Toxicol. 1993;73:103–8. doi: 10.1111/j.1600-0773.1993.tb01544.x.

Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/8248004/
resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/8248004
relatesTo
type: cites
classifier: Journal Article
citation:
Merkus FW, Verhoef JC, Marttin E, Romeijn SG, van der Kuy PH, Hermens WA, et al. Cyclodextrins in nasal drug delivery. Adv Drug Deliv Rev. 1999;36:41–57. doi: 10.1016/S0169-409X(98)00054-4.

Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/10837708/
resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/10837708
relatesTo
type: cites
classifier: Journal Article
citation:
Asai K, Morishita M, Katsuta H, Hosoda S, Shinomiya K, Noro M, et al. The effects of water-soluble cyclodextrins on the histological integrity of the rat nasal mucosa. Int J Pharm. 2002;246:25–35. doi: 10.1016/S0378-5173(02)00345-9.

Documents
- Url
* https://pubmed.ncbi.nlm.nih.gov/12270606/
resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/12270606
publicationForm
publishedIn
type: Periodical
identifier: Electronic ISSN Type/2050-6511, ISOAbbreviation/BMC Pharmacol Toxicol, ISSN Linking/2050-6511, Medline Title Abbreviation/BMC Pharmacol Toxicol, NLM Unique ID/101590449
title: BMC pharmacology & toxicology
publisherLocation: England
citedMedium: Internet
volume: 16
articleDate: 2015-10-26
publicationDateText: 2015-Oct-26
language: English
pageString: 29
publicationForm
citedMedium: Internet without issue
articleDate: 2015-10-26
webLocation
classifier: Abstract
url: https://pubmed.ncbi.nlm.nih.gov/26502880/
webLocation
classifier: DOI Based
url: https://doi.org/10.1186/s40360-015-0026-9
classification
type: Publishing Model
classifier: Electronic
classification
type: Chemical
classifier: Powders, beta-Cyclodextrins, Phosphorylcholine, dodecylphosphocholine, Glucagon, betadex
classification
type: MeSH heading
artifactAssessment: ArtifactAssessment: artifact[x] = this resource
classification
type: Publication type
classifier: Journal Article, Research Support, Non-U.S. Gov't
classification
type: Knowledge Artifact Type
classifier: Journal Article
artifactAssessment: Classifier added by Computable Publishing LLC
classification
type: Citation subset
classifier: IM
contributorship
complete: true
entry
contributor: Reno FE
forenameInitials: FE
affiliation: , 130 Macaw Lane, Merritt Island, FL, 32952, USA. freno1@cfl.rr.com.
entry
contributor: Normand P
forenameInitials: P
affiliation: ITR Laboratories Canada Inc. (ITR), 19601 Clark Graham Blvd, Baie d'Urfe, Quebec, Canada. pnormand@itrlab.com.
entry
contributor: McInally K
forenameInitials: K
affiliation: ITR Laboratories Canada Inc. (ITR), 19601 Clark Graham Blvd, Baie d'Urfe, Quebec, Canada. kmcinally@itrlab.com.
entry
contributor: Silo S
forenameInitials: S
affiliation: CiToxLAB North America, 445 Armand-Frappier Blvd, Laval, Québec, Canada. silos@ca.citoxlab.com.
entry
contributor: Stotland P
forenameInitials: P
affiliation: Locemia Solutions ULC., 8505 Dalton, Montreal, QC, Canada. patricia.stotland@locemia.com.
entry
contributor: Triest M
forenameInitials: M
affiliation: Locemia Solutions ULC., 8505 Dalton, Montreal, QC, Canada. myriam.triest@locemia.com.
entry
contributor: Carballo D
forenameInitials: D
affiliation: Locemia Solutions ULC., 8505 Dalton, Montreal, QC, Canada. dolores.carballo@locemia.com.
entry
contributor: Piché C
forenameInitials: C
affiliation: Locemia Solutions ULC., 8505 Dalton, Montreal, QC, Canada. claude.piche@locemia.com.

Generated Narrative: Practitioner #contributor0

name: Frederick E Reno

Generated Narrative: Practitioner #contributor1

name: Patrick Normand

Generated Narrative: Practitioner #contributor2

name: Kevin McInally

Generated Narrative: Practitioner #contributor3

name: Sherwin Silo

Generated Narrative: Practitioner #contributor4

name: Patricia Stotland

Generated Narrative: Practitioner #contributor5

name: Myriam Triest

Generated Narrative: Practitioner #contributor6

name: Dolores Carballo

Generated Narrative: Practitioner #contributor7

name: Claude Piché

Generated Narrative: ArtifactAssessment #meshHeading0

artifact: Citation 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.
content
type: components (if present) include qualifier codings
classifier: Administration, Intranasal
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Animals
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Area Under Curve
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Body Weight
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: drug effects
Components
- Type Classifier
* is Major topic No
content
type: components (if present) include qualifier codings
classifier: Dogs
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Female
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Glucagon
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: pharmacokinetics
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: toxicity
Components
- Type Classifier
* is Major topic Yes
content
type: components (if present) include qualifier codings
classifier: Humans
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Lung
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: drug effects
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: pathology
Components
- Type Classifier
* is Major topic No
content
type: components (if present) include qualifier codings
classifier: Male
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Metabolic Clearance Rate
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Models, Animal
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Organ Size
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: drug effects
Components
- Type Classifier
* is Major topic No
content
type: components (if present) include qualifier codings
classifier: Phosphorylcholine
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: analogs & derivatives
Components
- Type Classifier
* is Major topic Yes
component
type: qualifier
classifier: pharmacokinetics
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: toxicity
Components
- Type Classifier
* is Major topic No
content
type: components (if present) include qualifier codings
classifier: Powders
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: pharmacokinetics
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: toxicity
Components
- Type Classifier
* is Major topic Yes
content
type: components (if present) include qualifier codings
classifier: Rabbits
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Rats, Sprague-Dawley
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Species Specificity
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Survival Analysis
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Time Factors
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
type: components (if present) include qualifier codings
classifier: Toxicity Tests
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: methods
Components
- Type Classifier
* is Major topic No
content
type: components (if present) include qualifier codings
classifier: beta-Cyclodextrins
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: pharmacokinetics
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: toxicity
Components
- Type Classifier
* is Major topic Yes